VERTEX PHARMACEUTICALS INC / MA Quarterly Liabilities and Equity in USD from Q1 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Summary
Vertex Pharmaceuticals Inc / Ma quarterly Liabilities and Equity history and growth rate from Q1 2010 to Q3 2024.
  • Vertex Pharmaceuticals Inc / Ma Liabilities and Equity for the quarter ending September 30, 2024 was $22.2B, a 2.37% increase year-over-year.
Liabilities and Equity, Quarterly (USD)
Liabilities and Equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $22.2B +$514M +2.37% Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $20.1B -$217M -1.07% Jun 30, 2024 10-Q 2024-08-02
Q1 2024 $23.9B +$4.94B +26.1% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $22.7B +$4.58B +25.2% Dec 31, 2023 10-Q 2024-11-05
Q3 2023 $21.7B +$5.02B +30% Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $20.3B +$4.77B +30.6% Jun 30, 2023 10-Q 2023-08-02
Q1 2023 $19B +$4.72B +33.1% Mar 31, 2023 10-Q 2023-05-02
Q4 2022 $18.2B +$4.72B +35.1% Dec 31, 2022 10-K 2024-02-15
Q3 2022 $16.7B +$4.09B +32.4% Sep 30, 2022 10-Q 2022-10-28
Q2 2022 $15.6B +$3.36B +27.5% Jun 30, 2022 10-Q 2022-08-05
Q1 2022 $14.3B +$2.14B +17.7% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 $13.4B +$1.68B +14.3% Dec 31, 2021 10-K 2023-02-10
Q3 2021 $12.6B +$1.32B +11.7% Sep 30, 2021 10-Q 2021-11-03
Q2 2021 $12.2B +$2.01B +19.6% Jun 30, 2021 10-Q 2021-07-30
Q1 2021 $12.1B +$3.22B +36.2% Mar 31, 2021 10-Q 2021-04-30
Q4 2020 $11.8B +$3.43B +41.3% Dec 31, 2020 10-K 2022-02-09
Q3 2020 $11.3B +$3.79B +50.4% Sep 30, 2020 10-Q 2020-10-30
Q2 2020 $10.2B +$3.18B +45.3% Jun 30, 2020 10-Q 2020-07-31
Q1 2020 $8.89B +$2.35B +35.9% Mar 31, 2020 10-Q 2020-05-01
Q4 2019 $8.32B +$2.07B +33.2% Dec 31, 2019 10-K 2021-02-11
Q3 2019 $7.51B +$2.89B +62.6% Sep 30, 2019 10-Q 2019-10-31
Q2 2019 $7.03B +$2.7B +62.2% Jun 30, 2019 10-Q 2019-08-01
Q1 2019 $6.54B +$2.59B +65.5% Mar 31, 2019 10-Q 2019-05-01
Q4 2018 $6.25B +$2.7B +76.1% Dec 31, 2018 10-K 2020-02-13
Q3 2018 $4.62B +$1.42B +44.5% Sep 30, 2018 10-Q 2018-10-25
Q2 2018 $4.34B +$1.05B +32% Jun 30, 2018 10-Q 2018-07-26
Q1 2018 $3.95B +$1.01B +34.1% Mar 31, 2018 10-Q 2018-04-27
Q4 2017 $3.55B +$649M +22.4% Dec 31, 2017 10-K 2019-02-13
Q3 2017 $3.2B +$589M +22.6% Sep 30, 2017 10-Q 2017-10-30
Q2 2017 $3.29B +$737M +28.9% Jun 30, 2017 10-Q 2017-07-28
Q1 2017 $2.95B +$459M +18.4% Mar 31, 2017 10-Q 2017-04-28
Q4 2016 $2.9B +$398M +15.9% Dec 31, 2016 10-K 2018-02-15
Q3 2016 $2.61B +$176M +7.22% Sep 30, 2016 10-Q 2016-10-31
Q2 2016 $2.55B +$175M +7.37% Jun 30, 2016 10-Q 2016-08-01
Q1 2016 $2.49B +$322M +14.9% Mar 31, 2016 10-Q 2016-05-03
Q4 2015 $2.5B +$164M +7.02% Dec 31, 2015 10-K 2017-02-23
Q3 2015 $2.43B +$27.9M +1.16% Sep 30, 2015 10-Q 2015-10-30
Q2 2015 $2.37B +$256M +12.1% Jun 30, 2015 10-Q 2015-08-04
Q1 2015 $2.17B -$31.3M -1.42% Mar 31, 2015 10-Q 2015-05-04
Q4 2014 $2.33B +$15.6M +0.67% Dec 31, 2014 10-K 2016-02-16
Q3 2014 $2.41B -$177M -6.84% Sep 30, 2014 10-Q 2014-11-06
Q2 2014 $2.12B -$467M -18.1% Jun 30, 2014 10-Q 2014-07-31
Q1 2014 $2.2B -$195M -8.16% Mar 31, 2014 10-Q 2014-05-05
Q4 2013 $2.32B -$440M -16% Dec 31, 2013 10-K 2015-02-13
Q3 2013 $2.58B -$136M -5.01% Sep 30, 2013 10-Q 2013-11-07
Q2 2013 $2.58B -$20.5M -0.79% Jun 30, 2013 10-Q 2013-08-02
Q1 2013 $2.39B +$46.4M +1.98% Mar 31, 2013 10-Q 2013-05-08
Q4 2012 $2.76B +$555M +25.2% Dec 31, 2012 10-K 2014-02-11
Q3 2012 $2.72B +$627M +30% Sep 30, 2012 10-Q 2012-11-06
Q2 2012 $2.6B +$842M +47.7% Jun 30, 2012 10-Q 2012-08-08
Q1 2012 $2.35B +$807M +52.5% Mar 31, 2012 10-Q 2012-05-10
Q4 2011 $2.2B +$479M +27.8% Dec 31, 2011 10-K 2013-03-01
Q3 2011 $2.09B +$203M +10.8% Sep 30, 2011 10-Q 2011-11-03
Q2 2011 $1.76B +$109M +6.58% Jun 30, 2011 10-Q 2011-08-09
Q1 2011 $1.54B -$232M -13.1% Mar 31, 2011 10-Q 2011-05-06
Q4 2010 $1.73B Dec 31, 2010 10-K 2012-02-22
Q3 2010 $1.89B Sep 30, 2010 10-Q 2010-10-28
Q2 2010 $1.65B Jun 30, 2010 10-Q 2010-08-03
Q1 2010 $1.77B Mar 31, 2010 10-Q 2010-05-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.